NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-29 12:30இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Lincoln Pharma Q2 Revenue Up 17.1% YoY to ₹191.35 Cr; PAT Up 2.2% to ₹20.43 Cr
Lincoln Pharmaceuticals reported standalone Q2 FY27 revenue from operations of ₹191.35 crore, up 17.1% YoY compared to ₹163.36 crore in Q2 FY26. Standalone net profit stood at ₹20.43 crore, a modest increase of 2.2% YoY from ₹19.98 crore, but down 43.6% QoQ primarily due to higher other income recognized in the previous quarter. For H1 FY27, revenue reached ₹368.63 crore with net profit of ₹56.66 crore compared to ₹47.66 crore in H1 FY26. Diluted EPS for the quarter was ₹10.20 compared to ₹9.98 in the year-ago period.
உச்சம் நம்பிக்கை
என்ன மாறியதுLincoln Pharmaceuticals declared its unaudited standalone financial results for Q2 and H1 ended September 30, 2026.
ஏன் இது முக்கியம்Top-line growth remains steady at ~17% YoY, aligning with the company's 16% growth targets, though bottom-line growth slowed YoY in Q2 due to elevated operating and raw material expenses.
Q2 FY27 Revenue from Operations: ₹191.35 கோடிQ2 FY27 Net Profit: ₹20.43 கோடிH1 FY27 Revenue from Operations: ₹368.63 கோடிH1 FY27 Net Profit: ₹56.66 கோடிQ2 FY27 Diluted EPS: ₹10.20
📅 குறுகிய காலம்Likely neutral reaction as steady revenue growth is offset by flattish YoY profit and a sequential profit drop from Q1.
📈 நீண்ட காலம்Expansion into regulated markets (EU GMP, TGA Australia) and commercialization of new products provide steady growth potential toward targeted ₹750 Cr revenue.
⚠ அபாய எச்சரிக்கைகள்
Input cost inflation shown by higher cost of materials consumed (₹77.47 Cr vs ₹57.20 Cr YoY)
Foreign exchange volatility affecting export realizations across 60+ destination markets
👀 கவனிக்க வேண்டியவை
Track the pace of export penetration into regulated markets following EU GMP and TGA Australia approvals, as well as operational margin stability across H2 FY27.
Lincoln Pharma Sets Sept 11, 2026 as Record Date for ₹1.80/Share (18%) Final Dividend
Lincoln Pharmaceuticals Limited has fixed Friday, September 11, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹1.80 per equity share (18% on face value of ₹10) for FY 2025-26. The payment remains subject to shareholder approval at the company's 32nd Annual General Meeting scheduled for September 30, 2026. At the current market price of ₹615, the dividend translates to a dividend yield of ~0.29%. The share transfer books will remain closed from September 12, 2026, to September 30, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுLincoln Pharma has formalized the record date and AGM timeline for the distribution of its FY26 final dividend.
ஏன் இது முக்கியம்Defines the exact cut-off timeline for shareholders to receive the ₹1.80 per share cash distribution from FY26 profits.
Final dividend per share: ₹ 1.80Dividend percentage: 18%ரெக்கார்ட் தேதி: 11-செப்.-2026AGM date: 30-செப்.-2026Dividend yield at ₹615: ~0.29%
📅 குறுகிய காலம்Stock will trade ex-dividend leading into the September 11, 2026 record date with negligible price impact given the small yield (~0.29%).
📈 நீண்ட காலம்Limited; routine annual capital allocation and dividend distribution.
👀 கவனிக்க வேண்டியவை
Investors tracking dividend payouts should note the September 11, 2026 record date and track the outcome of the 32nd AGM on September 30, 2026.
31% YoY PAT Growth in Q1 FY27; Revenue Rises 15% to ₹177.3 Cr
Lincoln Pharmaceuticals reported a strong start to FY27 with a 30.9% YoY increase in Net Profit to ₹36.23 Cr. Revenue from operations grew 15.1% YoY to ₹177.28 Cr, representing approximately 26.4% of its TTM revenue. Profitability was significantly higher than the preceding quarter (Q4 FY26 PAT was ₹11.63 Cr), supported by a recovery in margins. The company maintains a robust financial position with a near-zero debt-to-equity ratio of 0.01.
உச்சம் நம்பிக்கை
என்ன மாறியதுLincoln Pharmaceuticals released its Q1 FY27 results, showing a significant recovery in profitability compared to the previous quarter and strong double-digit growth on a YoY basis.
ஏன் இது முக்கியம்The results demonstrate the company's ability to scale its formulations business and maintain margins despite a high export exposure (60+ countries). The strong EPS growth supports the current P/E valuation of 13.9x.
Revenue (Q1 FY27): ₹177.28 கோடிNet Profit (Q1 FY27): ₹36.23 கோடிYoY PAT Growth: 30.9%Q1 வருவாய் vs TTM வருவாய்: 26.4%EPS (Q1 FY27): ₹18.09
📅 குறுகிய காலம்The stock may see positive sentiment in the short term as the market reacts to the 31% YoY profit growth and the sharp sequential recovery from Q4 FY26.
📈 நீண்ட காலம்Structural growth depends on the successful entry into high-value regulated markets like Canada, Australia, and the EU, alongside the shift toward high-margin chronic and lifestyle segments.
Regulatory risks associated with EU GMP and TGA standards
👀 கவனிக்க வேண்டியவை
Monitor the commercialization timeline of the Cephalosporin plant and the progress of the 700-product R&D pipeline, which are critical for reaching the management's ₹750 Cr revenue target.
Lincoln Pharma Recommends ₹1.80 Dividend; FY26 Net Profit Rises to ₹87.89 Crore
Lincoln Pharmaceuticals reported a steady performance for the full year ended March 31, 2026, with total income growing 9.1% to ₹704.48 crore. The company's annual net profit increased by 6.7% year-on-year to ₹87.89 crore, resulting in an improved EPS of ₹43.88. A final dividend of ₹1.80 per share (18%) has been recommended for shareholder approval. While annual growth is positive, the Q4 net profit remained relatively flat at ₹11.63 crore compared to the same period last year.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.80 per equity share (18% of face value) for FY26.Annual Revenue from Operations grew 7.7% year-on-year to ₹671.03 crore.Full-year Net Profit increased to ₹87.89 crore from ₹82.35 crore in the previous fiscal.Earnings Per Share (EPS) improved to ₹43.88 from ₹41.11 in FY25.Cash and cash equivalents increased to ₹21.09 crore as of March 31, 2026, up from ₹12.97 crore.
👀 கவனிக்க வேண்டியவை
Investors should consider the steady growth and consistent dividend payout as a sign of financial stability. The stock remains a solid hold for long-term investors given the healthy balance sheet and moderate earnings growth.
Lincoln Pharma Q3 FY26 Net Profit Rises 37.7% to INR 28.6 Cr; Eyes INR 1,000 Cr Revenue Target
Lincoln Pharmaceuticals reported a strong Q3 FY26 with revenue growing 13.5% YoY to INR 166.32 crores and net profit jumping 37.7% to INR 28.60 crores. The management maintains a long-term revenue target of INR 1,000 crores, driven by the expansion of the Cepha block and entry into regulated markets. A new R&D center is expected to be operational within 2.5 months to support niche therapeutic product development. The company remains debt-free with significant cash reserves being deployed for potential inorganic growth opportunities.
முக்கிய அம்சங்கள்
Net Profit increased by 37.7% YoY to INR 28.60 crores in Q3 FY26 compared to INR 20.77 crores in Q3 FY25.Revenue from operations grew to INR 166.32 crores from INR 146.55 crores in the previous year.Cepha block revenue is targeted to reach INR 90-100 crores next year, up from the current INR 45 crores.EPS for the 9-month period reached INR 38.07, nearly matching the previous full year's EPS of INR 41.11.Company is debt-free and exploring inorganic growth opportunities using substantial cash reserves yielding 10-12% returns.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the new R&D center and the ramp-up of the Cepha block as key drivers for the INR 1,000 crore revenue goal. The company's debt-free status and strong cash position provide a safety margin for long-term growth.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Lincoln Pharma Q3 Net Profit Surges 37.7% YoY to ₹28.6 Crore; Revenue Up 13.5%
Lincoln Pharmaceuticals reported a strong performance for the quarter ended December 31, 2025, with consolidated net profit rising 37.7% YoY to ₹28.60 crore. Revenue from operations grew by 13.5% YoY to ₹166.32 crore, supported by steady growth in its core pharmaceutical business. The company's profitability improved significantly on a sequential basis, with net profit jumping 43.1% compared to the previous quarter. For the nine-month period, the company maintained a healthy trajectory with a net profit of ₹76.26 crore on revenues of ₹483.75 crore.
முக்கிய அம்சங்கள்
Consolidated Revenue from Operations grew 13.5% YoY to ₹166.32 crore in Q3 FY26Net Profit for the quarter stood at ₹28.60 crore, up from ₹20.77 crore in the same period last yearEarnings Per Share (EPS) increased to ₹14.28 from ₹10.37 in Q3 FY25Profit Before Tax (PBT) rose to ₹34.72 crore, reflecting improved operational efficiencyNine-month (9M FY26) revenue reached ₹483.75 crore with a net profit of ₹76.26 crore
👀 கவனிக்க வேண்டியவை
The strong YoY and QoQ growth in profitability suggests robust operational performance. Investors should monitor the sustainability of these margins and the company's expansion in the pharmaceutical segment.
CRISIL Reaffirms Lincoln Pharmaceuticals' Credit Rating at 'CRISIL A/Stable' and 'CRISIL A1'
CRISIL has reaffirmed Lincoln Pharmaceuticals' long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for its Rs 102 crore bank facilities. The company maintains a robust financial profile with zero debt and a healthy net worth of Rs 671 crore as of March 31, 2025. Revenue grew by 14% YoY to Rs 623 crore in FY25, supported by a strong export presence contributing 60-65% of total sales. While the liquidity position is strong with Rs 173.1 crore in liquid investments, investors should monitor the increase in loans to affiliates, which rose to Rs 141 crore.
முக்கிய அம்சங்கள்
CRISIL reaffirmed long-term rating at 'CRISIL A/Stable' and short-term rating at 'CRISIL A1' for Rs 102 crore facilities.Company reported zero debt as of March 31, 2025, with a high interest coverage ratio of 91.01 times.Revenue grew 14% year-on-year to Rs 623.23 crore in FY25, driven by 1,700 registered products.Liquid investments in shares, debentures, and mutual funds stood at Rs 173.1 crore.Loans and advances to affiliates increased to Rs 141 crore from Rs 104 crore in the previous year.
👀 கவனிக்க வேண்டியவை
The reaffirmation of ratings and zero-debt status highlights the company's strong solvency and financial health. Investors should remain positive but monitor the rising loans to affiliates and the working capital cycle.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
